Latest news with #NileshGupta
&w=3840&q=100)
Business Standard
01-07-2025
- Business
- Business Standard
Lupin carves out consumer healthcare biz into wholly owned subsidiary
Mumbai-based pharmaceutical major Lupin on Tuesday announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare (LCH), into a wholly owned subsidiary. The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges. The company said the initiative aligns with its aspiration to establish a specialised consumer healthcare entity, with an enhanced focus on India's rapidly growing self-care market. 'This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth,' Lupin said in a statement. Since its inception in 2017, LCH has developed a strong over-the-counter (OTC) portfolio, which includes brands such as Softovac, Beplex Forte, Corcium, and Aptivate. Commenting on the development, Nilesh Gupta, Managing Director at Lupin, said the move reinforces the company's mission of developing high-impact businesses that drive sustained value. While revenue for Lupin's consumer healthcare business is not reported separately, the company recorded a 13.47 per cent rise in total revenue from operations, from ₹2 trillion in financial year 2023–24 (FY24) to ₹2.27 trillion for FY25. The growth in FY25 was led by strong sales and profitability, driven by in-line and new products, along with consistent improvement in operating margins. On Tuesday, Lupin's shares rose 1.21 per cent to close at ₹1,961.30 apiece on the Bombay Stock Exchange (BSE).
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%
Mumbai-based pharma giant Lupin on Tuesday reported a sharp 112.4 per cent on-year rise in its consolidated net profit at ₹782.4 crore for the fourth quarter of financial year 2025 (Q4FY25), up from ₹368.2 crore recorded for the same period last year. The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24. Sequentially, the company's profit and revenue fell by 8.9 per cent and 1.7 per cent. On an operational basis, Lupin's earnings before interest, tax, deduction and amortisation (Ebitda) rose by 34.3 per cent Y-o-Y to ₹1,371 crore, from ₹1,026 crore in Q4FY24, with Ebitda margin rising to 24.8 per cent from 21 per cent. Commenting on the results, Nilesh Gupta, Managing Director at Lupin said FY25 was led by strong growth in sales and profitability driven by in-line and new products, and consistent improvement in operating margins backed by strong commercial momentum and operational efficiencies. The pharma major also saw a double digit increase in its formulations business for the March quarter, with sales rising by 15 per cent Y-o-Y to ₹5,330.6 crore from ₹4,367 crore in Q4FY24. In terms of geographies, North America accounted for 41 per cent of Lupin's total global sales in Q4FY25 at ₹2,261.8 crore. This is a 19.0 per cent rise compared to ₹1,900 crore in Q4FY24. The company added that it continues to be the third largest pharmaceutical player in both the US generic market and US total market by prescriptions. In India, Lupin's formulation sales went up 6.9 per cent to ₹1,711.3 crore from ₹1,601.5 crore in the same quarter last year, contributing 31 per cent to its global sales. Sales revenue from other developed markets rose to ₹691.5 crore in the fourth quarter, a 30 per cent rise from ₹531.8 crore. On the other hand, Lupin's active pharmaceutical ingredients (API) business saw a 10.3 per cent on-year fall to ₹231.6 crore from ₹258.1 crore for the same period last year. The company announced its results post the market hours. On Wednesday, Lupin's shares rose marginally by 0.44 per cent, closing at ₹2.072 apiece on the Bombay Stock Exchange (BSE).
